VRTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Vertex Pharmaceuticals Inc (VRTX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows strong bullish momentum, positive financial performance, and favorable analyst sentiment, making it a solid choice for long-term growth.
The stock is in a bullish trend with MACD histogram at 0.515 (positive and expanding), RSI at 72.089 (neutral zone), and bullish moving averages (SMA_5 > SMA_20 > SMA_200). The current price of $494.82 is above the pivot level ($473.949), with resistance levels at $490.432 and $500.615, indicating strong upward momentum.
Strong Q4 2025 revenue growth of 9.55% YoY to $3.19 billion.
Positive analyst sentiment with multiple upgrades and increased price targets (e.g., Barclays raised the target to $606, RBC to $546).
Promising pipeline developments, including cystic fibrosis and renal franchise advancements.
Projected 2026 revenue of $12.95-$13.1 billion, with at least $500 million from non-cystic fibrosis treatments.
Hedge funds have significantly increased selling activity (up 149.17% over the last quarter).
Q4 non-GAAP EPS of $5.03 missed estimates by $0.
Gross margin slightly declined to 85.39% (-0.08% YoY).
Vertex Pharmaceuticals reported strong financials for Q4 2025, with revenue up 9.55% YoY to $3.19 billion, net income up 30.46% YoY to $1.191 billion, and EPS up 30.99% YoY to $4.65. However, gross margin slightly declined to 85.39%. The company projects 2026 revenue between $12.95 billion and $13.1 billion, aligning with consensus estimates.
Analysts are overwhelmingly bullish on Vertex Pharmaceuticals, with multiple upgrades and price target increases. Recent upgrades include Barclays raising the target to $606 (from $414) and RBC to $546 (from $455). Analysts highlight the company's strong cystic fibrosis business, promising pipeline, and undervaluation in the biotech sector as key drivers for growth.
